ViroPharma Provides 2008 Outlook( 2008 Focus on Pipeline Advancement;...)

2008 Focus on Pipeline Advancement; CAMVIA Momentum Building Toward 2009

NDA

EXTON, Pa., Jan. 9 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced Michel de Rosen, ViroPharma's president and chief executive officer, will provide an overview of the company's business and present a financial update during the 26th Annual JPMorgan Healthcare Conference. As previously announced, this presentation will be webcast live at 2:00 P.M. Pacific Time on Wednesday, January 9, 2008 and may be accessed via the company's website at http://www.viropharma.com. The company expects to release full-year 2007 financial results and further discuss 2008 guidance later in the first quarter of 2008.

"We are in the midst of a period of great momentum and promise," said Michel de Rosen, ViroPharma's Chief Executive Officer. "For example, we expect to build on the great clinical progress we are currently experiencing in our ongoing Phase 3 program with CAMVIA(TM)(maribavir) as we move toward our goal of a 2009 NDA filing. We also continue to work diligently in our pre-launch activities for CAMVIA to refine our plans for medical education, marketing and communications, and ensure a successful launch. We also are extremely excited about moving our unique non-toxigenic C. difficile (NTCD) program into humans during the year; we believe that this novel approach could one day be the therapy of choice for recurrent C. difficile infection (CDI), which remains a significant medical need in CDI patients. As a reminder, we along with Wyeth continue to work diligently to elucidate the path forward for our HCV program which we hope will reinvigora
'/>"/>